Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
5(38%)
Results Posted
100%(1 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
6
46%
Ph phase_4
1
8%
Ph phase_1
2
15%
Ph phase_3
2
15%
Ph not_applicable
1
8%

Phase Distribution

2

Early Stage

6

Mid Stage

3

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
6(50.0%)
Phase 3Large-scale testing
2(16.7%)
Phase 4Post-market surveillance
1(8.3%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

5

trials recruiting

Total Trials

13

all time

Status Distribution
Active(7)
Completed(1)
Terminated(1)
Other(4)

Detailed Status

unknown4
Active, not recruiting3
Not yet recruiting2
Recruiting2
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
5
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (16.7%)
Phase 26 (50.0%)
Phase 32 (16.7%)
Phase 41 (8.3%)
N/A1 (8.3%)

Trials by Status

not_yet_recruiting215%
active_not_recruiting323%
recruiting215%
completed18%
unknown431%
terminated18%

Recent Activity

5 active trials
Showing 5 of 13
not_yet_recruitingphase_2

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

NCT07468916
recruitingphase_1

Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

NCT07047885
active_not_recruiting

Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)

NCT06506084
terminatedphase_2

P1101 in Treating Patients With Myelofibrosis

NCT02370329
recruitingphase_3

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

NCT06468033
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT07468916Phase 2

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Not Yet Recruiting
NCT07047885Phase 1

Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

Recruiting
NCT06506084

Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)

Active Not Recruiting
NCT02370329Phase 2

P1101 in Treating Patients With Myelofibrosis

Terminated
NCT06468033Phase 3

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Recruiting
NCT04285086Phase 3

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Active Not Recruiting
NCT05485948Phase 2

A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU

Active Not Recruiting
NCT06290765Phase 4

Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera

Not Yet Recruiting
NCT05808322Phase 2

Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities

Unknown
NCT05467553Phase 2

A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection

Unknown
NCT05494528Not Applicable

Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy

Unknown
NCT04988815Phase 2

Ropeginterferon Alfa 2b for Early Myelofibrosis

Unknown
NCT03546465Phase 1

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects

Completed

All 13 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
13